TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06124521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ComBaT Glaucoma
Description: ComBaT Glaucoma is a personalized counseling and education program about the participant's diagnosis and the importance of glaucoma follow-up care in maintaining vision.
Study: NCT05157620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga-based Exercise (YE)
Description: The Yoga-based Exercise (YE) intervention is a series of yoga-based poses that consists of sitting, standing, kneeling, and lying postures as well as breathing exercises. The duration of the intervention will be 12 months. Participants will engage in yoga-based exercise sessions lasting 60 minutes twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in yoga-based exercises once a week. The remainder of the study (6 months), participants will engage in yoga-based exercises once a month.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Lifestyle Program (WLP)
Description: The Wellness Lifestyle Program (WLP) is a comprehensive lifestyle program that consists of 30 minutes of educational information covering various topics, such as nutrition, healthy living, stress reduction, and more will be followed by 30 minutes of low-intensity exercise such as walking. The duration of the intervention will be 12 months. Participants will engage in the 60 minute WLP session twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in WLP sessions once a week. The remainder of the study (6 months), participants will engage in WLP sessions once a month.
Study: NCT05276622

Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment
Description: A modified Cancer and Aging Research Group (CARG) Geriatric Assessment that includes validated measures of 7 geriatric domains: functional status, comorbidity, cognition, psychological state, social activity, and support, nutritional status, and medications will be performed at baseline (pre-treatment), every 3 months for a total of 3 assessments. The modified comprehensive Geriatric Assessment includes patient-reported surveys and research staff assessments.~Cognitive Testing: The National Institutes of Health Toolbox Cognition Battery (objective) and PROMIS Short Form v2.0 - Cognitive function 8a (subjective)

Intervention type: OTHER
Intervention: Qualitative patient-care partner interviews
Description: Semi-structured Interviews: Baseline and again at 3 months.

Intervention type: OTHER
Intervention: Surveys on well-being and function
Description: Care partner's Surveys on well-being and function: Baseline and again at 3 months
Study: NCT06042361

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smokefree Implementation Framework and Toolkit
Description: Framework and toolkit that includes Implementation Guide, Action Plan, and Implementation Checklist that supports the needs of Permanent Supportive Housing communities.
Study: NCT06293040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be vaporized using the Mighty Medic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be vaporized using the Mighty Medic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be vaporized using the Mighty Medic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be vaporized using the Mighty Medic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol will be orally ingested via a flavored drink

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol will be orally ingested via a flavored drink

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol will be orally ingested via a flavored drink

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol will be orally ingested via a flavored drink

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Cannabis
Description: Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Cannabis
Description: Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cannabis
Description: Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Alcohol
Description: A non-alcoholic, placebo, flavored drink will be orally ingested.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Alcohol
Description: A non-alcoholic, placebo, flavored drink will be orally ingested.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Alcohol
Description: A non-alcoholic, placebo, flavored drink will be orally ingested.
Study: NCT06364592

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Hwato brand disposable acupuncture needles (size 0.30 × 40 mm and 0.30 × 75 mm) and SDZ-V electroacupuncture apparatus will be used. Acupoints of Ciliao (BL32), Shiqizhui (EX-B8), and Sanyinjiao (SP6) will be used for participants.~The needles will be inserted to 60-70mm in BL32 and 25-30mm in EX-B8 and SP6. Needle manipulation will be conducted (except for BL32) to achieve deqi sensation. Then paired electrodes from the electroacupuncture apparatus will be attached transversely to the needle handles at bilateral BL32 and SP6. The electroacupuncture stimulation will last for 30 minutes with a continuous wave of 5Hz and a current intensity of 1 to 5mA. Current intensity was adjusted according to the patients' individual tolerance.Treatment will start within one week before the onset of menstruation and stop before the end of menstruation, three sessions per menstrual cycle in total (ideally every two to three days and at least one session during menstruation period).
Study: NCT06305312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Service Navigation
Description: Patients randomized to the intervention will be directly referred to the United Way of Salt Lake's 211 community referral service for additional outreach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard referral to community resources.
Study: NCT05756127

Intervention type: OTHER
Intervention: Observational - no intervention given
Description: Observational - no intervention given
Study: NCT06364592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Electroacupuncture
Description: Hwato brand disposable acupuncture needles (size 0.25 × 40 mm and 0.30 × 25 mm) and SDZ-V electroacupuncture apparatus will be used. Sham acupoints of BL32, EX-B8 and SP6 will be used for every participants.~The needles will be inserted to 2-3mm in sham acupoints. Procedures, electrode placements, and other treatment settings were the same as in the electroacupuncture group but with no electricity output or needle manipulation for de qi.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Electroacupuncture
Description: Hwato brand disposable acupuncture needles (size 0.25 × 40 mm and 0.30 × 25 mm) and SDZ-V electroacupuncture apparatus will be used. Sham acupoints of BL32, EX-B8 and SP6 will be used for every participants.~The needles will be inserted to 2-3mm in sham acupoints. Procedures, electrode placements, and other treatment settings were the same as in the electroacupuncture group but with no electricity output or needle manipulation for de qi.
Study: NCT06381817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haplo-cord HCT
Description: Haploidentical hematopoietic cell transplantation will be performed with coinfusion of an unrelated cord blood unit

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haplo-HCT
Description: Hematopoietic cell transplantation will be performed with a haploidentical donor
Study: NCT06317064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen and Aprepitant
Description: All 30 participants in this group used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Same patients from phase 2 (n=30) in next cycle received NK1R antagonist Dexamethasone (6mg) + Aprepitant (80mg) for 2 days.
Study: NCT05691348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulatory appendectomy
Description: Appendectomy will be performed in outpatient surgery unit. Patient will be discharge from the hospital the same day as surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional appendectomy
Description: Appendectomy will be performed in digestive surgery department. Patient will be discharge from the hospital the day after surgery: he will spend a night under observation
Study: NCT04700397

Intervention type: DIAGNOSTIC_TEST
Intervention: Nitroglycerine
Description: We aim to test the repeatability of NTG-Pd/Pa with different dosages of nitroglycerine injection.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nitroglycerine
Description: We aim to test the repeatability of NTG-Pd/Pa with different dosages of nitroglycerine injection.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nitroglycerine
Description: We aim to test the repeatability of NTG-Pd/Pa with different dosages of nitroglycerine injection.
Study: NCT06411210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector
Description: Escalated to 2.4mg or max tolerated dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo.
Study: NCT04930185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme
Description: Participants will be receiving the pamphlet about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme
Description: Participants will be receiving the webinar last for half an hour about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme
Description: Participants will be receiving the SMS about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated.
Study: NCT04933162

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Protein and Low Fiber Diet
Description: Protein intake will be increased to be \>40% calories from protein, and the fiber intake will remain \<15gm/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Protein and High Fiber Diet
Description: Increase fiber intake up to 40gms of fiber with a requirement to increase at least 15gms above baseline fiber, with 50-75% of total fiber intake from psyllium husk. Subjects will be allowed to slowly increase fiber every two days to reach goal by end of week 1. The total protein will be reduced to \<10% total calories from protein.
Study: NCT04961983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Travel Health Education Model
Description: The comprehensive travel health education model consists of:~1. Online training: 10 hours (2 days) online education via Zoom. The topics that will be delivered during the training includes:~   * The potential roles of tour guides in tourists' health,~  * The importance of travel health information for tourists,~  * Assessment of tourist's health risks,~  * Prevention and first aid of various travel health problems Topics related to tour guides will be delivered by the tourism experts, while topics related to travel health will be provided by travel medicine experts, Faculty of Medicine, Udayana University. Participants will also receive a travel health guide book.~2. Weekly travel health Information sharing through WhatsApp group for 2 months.
Study: NCT05625568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VYNT-0126
Description: Liquid for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VYNT-0126
Description: Liquid for oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid for oral administration once daily
Study: NCT05648136

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: Blood sampling by venipuncture will be performed :~* for patients and controls: between the 20th and 24th day of the menstrual cycle (implantation window) preceding the following IVF+/-ICSI cycle~* for patients receiving an endometrial biopsy: on the same day as the endometrial biopsy~* for patients and controls receiving follicular stimulation for ovarian puncture: the day of the oocyte puncture~* for patients and controls undergoing embryo transfer: on the day of embryo implantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Blood sampling by venipuncture will be performed :~* for patients and controls: between the 20th and 24th day of the menstrual cycle (implantation window) preceding the following IVF+/-ICSI cycle~* for patients receiving an endometrial biopsy: on the same day as the endometrial biopsy~* for patients and controls receiving follicular stimulation for ovarian puncture: the day of the oocyte puncture~* for patients and controls undergoing embryo transfer: on the day of embryo implantation
Study: NCT05663944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2nd Percutaneous or Endoscopic Ultrasound guided liver biopsy
Description: All participants will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate when compared to their first biopsy.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: 1st MRI scan
Description: If participants opt in for MRI scans, a non-contrast MRI scan will be repeated at the end of the trial, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
Study: NCT06406998

Intervention type: OTHER
Intervention: Pre-existing atherosclerotic cardiovascular disease
Description: Presence of pre-existing atherosclerotic cardiovascular disease
Study: NCT06476626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Reflective Function Workshop
Description: 4 session group online intervention focused on psycho-educational knowledge regarding emotional regulation and specifically MRF. group size- up to 15 participants. 2 sessions will be during pregnancy and 2 sessions will taken place 1 and 3 months after birth.
Study: NCT05391321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: administration of the 4 quality of sexual life questionnaires
Description: administration of the 4 quality of sexual life questionnaires
Study: NCT06297681

Intervention type: DRUG
Intervention: Daratumumab + Bortezomib + Dexamethasone + Dapagliflozin
Description: The treatment medication for enrolled patients must comply with the treatment regimen of Daratumumab + Bortezomib + Dexamethasone: subcutaneous injection of 1800mg of Daratumumab, d1, 8,15,22 (28 day cycle); (After 2 cycles of improvement in cardiac indicators, it can be adjusted to intravenous injection of daratumumab); Bortezomib 1.3 mg/m2 d1, 8, 15, 22; D1, 8, 15, 22; Dexamethasone 20 mg d1, 2, 8, 9, 15, 16, 22, 23. When NTProBNP is greater than 5400ng/ml, bortezomib 1.0mg/m2; When NTProBNP is greater than 8500ng/ml, bortezomib is 0.7mg/m2. When NTProBNP is greater than 10000ng/ml, bortezomib is temporarily not allowed; NTProBNP greater than 4500ng/ml dexamethasone starts at 10 mg/dose. All patients were given Dapagliflozin 10mg/day at the beginning of treatment (creatinine clearance rate greater than 20ml/min).
Study: NCT05663944

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 1st MRI scan
Description: If participants opt in for MRI scans, a non-contrast MRI scan will be repeated at the end of the trial, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
Study: NCT06428721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Laser Resurfacing
Description: A rejuvenating laser that makes tiny holes in the very superficial part of the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Laser Resurfacing
Description: A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
Study: NCT06643416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5% eye drops and betamethasone valerate 0.1% cream
Description: Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.

Intervention type: DRUG
Group type: OTHER
Intervention: Betamethasone valerate 0.1% cream
Description: The management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone valerate 0.1% cream
Description: The management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.
Study: NCT06645054

Intervention type: BEHAVIORAL
Intervention: Standard rehabilitation
Description: The patients will receive standard rehabilitation that comprises assessment performed by a multidisciplinary team (physical-and-rehabilitation-medicine specialist physician, physiotherapist, occupational therapist, psychologist, social worker, prosthetics-and-orthotics engineer).

Intervention type: BEHAVIORAL
Intervention: Standard rehabilitation
Description: The patients will receive standard rehabilitation that comprises assessment performed by a multidisciplinary team (physical-and-rehabilitation-medicine specialist physician, physiotherapist, occupational therapist, psychologist, social worker, prosthetics-and-orthotics engineer).

Intervention type: DEVICE
Intervention: Lower-limb prosthesis
Description: The patients from the LLL group will be fitted with an appropriate lower-limb prosthesis.

Intervention type: DEVICE
Intervention: Lower-limb orthosis
Description: The patients from the LLO group will be fitted with an appropriate lower-limb orthosis.
Study: NCT05556850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STABL Virtual Rehabilitation
Description: STABL is a digital health platform that uses computer-vision technology to facilitate at-home post-op recovery for patients while enabling remote monitoring by their surgeon. The platform is fully HIPAA compliant.~STABL analyzes a patient's biomechanics in real time while they perform their recovery exercises to provide them with cues to ensure the exercises are done correctly and track adherence. They then relay all the data to the patient's clinician to allow them to monitor their recovery remotely, address any adherence barriers, and mitigate readmission risks that arise in a more timely manner.
Study: NCT05304949

Intervention type: OTHER
Intervention: Lucentis
Description: There is no treatment allocation. Patients administered Lucentis by prescription will be enrolled.
Study: NCT04620590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG [Farxiga]
Description: Dapagliflozin is a stable, reversible, highly selective, and orally active inhibitor of human renal sodium glucose co-transporter 2 (SGLT2), the major transporter responsible for glucose reabsorption in the kidney. Patients will receive one tablet dapagliflozin 10 mg per day for a total period of 14±1 days. This dose is the recommended dose for monotherapy and for add-on combination therapy with other glucose-lowering medicinal products including insulin to improve glycaemic control in T2DM.
Study: NCT05359549

Intervention type: DEVICE
Intervention: Two endosseous dental implants (NobelReplace Groovy®) were placed 10 years ago
Description: All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of having two failing teeth in the maxillary aesthetic region and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
Study: NCT06463418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekoskeleton (Intervention)
Description: Exoskeleton walking three times per week for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation (Comparator)
Description: Relaxation three times per week for 12 weeks.